Background and Purpose-Several accepted algorithms exist to characterize the risk of thromboembolism in atrial fibrillation. We performed a comparative analysis to assess the predictive value of 9 such schemes. Methods-In a longitudinal community-based cohort study from Olmsted County, Minnesota, 2720 residents with atrial fibrillation were followed up for 4.4±3.6 years±SD from 1990 to 2004. Risk factors were identified using a diagnostic index integrated with the electronic medical record. Thromboembolism and cardiovascular event data were collected and analyzed. 
A trial fibrillation (AF) is the most common sustained cardiac rhythm, and its presence is associated with 15% to 20% of all strokes in the United States. 1, 2 Not all patients share the same risk profile for thromboembolic stroke, and oral anticoagulation is recognized as a mainstay of therapy in certain groups. [3] [4] [5] Numerous risk stratification schemes have been developed to improve the accuracy of risk categorization on the basis of both evidence and expert consensus. More recently, the CHADS 2 risk score 6 has been validated in several studies [7] [8] [9] [10] [11] [12] and is among the most widely used. The European Society of Cardiology (ESC) has recently adopted a new risk schemathe CHA 2 DS 2 -VASc score. 13 , 14 The goal of this study is to compare the accuracy of the risk stratification of 9 well-known risk stratification schemes, including the CHADS 2 and CHA 2 DS 2 -VASc scores (Table 1) , in a well-characterized communitybased cohort. 15 
Methods
This study is a retrospective review of a community-based cohort of 2720 adults with nonvalvular AF from Olmsted County, Minnesota, who were followed up from 1990 to 2004. This cohort of subjects has clinical data centralized via a medical record linkage system, confirmed and validated in numerous previous studies. 15 Institutional review board approval was obtained. Only patients with a first episode of documented AF attributable to a nonreversible cause were included in the study. Patients with atrial flutter without AF or valvular heart disease were excluded from analysis.
Identification of Thromboembolic Events
Medical records were examined for documentation of thromboembolism, and ischemic stroke was defined as the acute onset of a focal neurological deficit lasting ≥24 hours and corresponded to a vascular distribution affecting the brain, cerebellum, or brain stem. Stroke events were diagnosed by computed tomography or MRI imaging or clinical diagnosis by a neurologist. Hemorrhagic strokes, confirmed by computed tomography or MRI imaging, were excluded from analysis. Peripheral arterial thromboembolic events were also included if no other obvious causes was found. In patients with multiple events, only the first event was recorded.
Statistical Analysis
Basic statistics, mean±SD for continuous data and frequency (%) for categorical data, were used to describe the patient demographic characteristics. Univariate and multivariate Cox modeling were used to identify risk factors for thromboembolic events (Table 3) . Cox proportional hazard model and c statistics with Harrell 95% confidence intervals (CIs) were used to measure the risk prediction abilities of the different risk stratification schemes. 19, 20 Any P value <0.05 was considered statistically significant. All statistical analyses were performed by SAS version 9.3 software (SAS Institute Inc, Cary, NC).
Results
A total of 2720 patients were confirmed to have first AF from the years of 1990 to 2000 and were followed until death or 2004. Mean duration of follow-up was 4.37±3.55 years±SD with a total of 11 886 person-years (PY) analyzed. Mean age was 73±14 years and 1320 patients (48.5%) were women. A total of 1490 patients (54.8%) were aged ≥75 years at inclusion. Mean systolic blood pressure was 138±20 mm Hg at inclusion and 2259 patients (83%) had been diagnosed with hypertension. A total of 700 (26%) had a history of previous or concurrent heart failure. Diabetes mellitus was present in 511 patients (19%), and 1544 (57%) were past or current smokers. Paroxysmal AF was diagnosed in 75% patients. In addition, 313 patients (12%) also had the diagnosis of atrial flutter. At the time of inclusion, 147 patients (5%) were already on warfarin and 783 (29%) were on aspirin. A total Table I in the online-only Data Supplement. The percentage of patients classified as low risk at inclusion differed considerably among the risk stratification schemes. Several schemes categorized <10% of all patients in the low-risk category: CHA 2 DS 2 -VASc (5%), National Institute to Health and Clinical Excellence (NICE; 7%), and AF Investigators (8%), and the greatest proportion in this category was in the Stroke Prevention in AF (SPAF) classification (14%; Table 4 ).
Univariable analysis of the entire cohort identified age >75 years, female sex, history of transient ischemic attack, history of hypertension, diabetes mellitus, history of heart failure, and vascular disease as risk factors for thromboembolism (Table 3) Table 5 ). The SPAF scheme had the highest concordance when calculated with Harrell c statistic (c=0.659; 95% CI, 0.634-0.684). Other methods performed similarly (Table 5) .
Discussion
This study compares the performance of 9 stroke risk stratification schemes in AF on a well-validated community-based cohort. Hypertension, age, diabetes mellitus, history of congestive heart failure, and female sex were the only significant predictors of clinical thromboembolism on multivariable analysis, consistent with risk factors identified by previous investigations.
13, 16 The percentage of patients in each risk group is similar to previous studies. 9, 10, 12, 21 patients similarly, likely a consequence of being based on the CHADS 2 scoring system.
The c statistic represents the area under the receiveroperator characteristic curve. Stroke risk discrimination among the different risk schemes was similar in our population to published c statistics in other populations of both patients on and off anticoagulation, 9,12,22-24 although no accepted c statistic method exists, and comparisons between studies are limited by the heterogeneity between study populations.
A recent Markov analysis 25 prompted by the emergence of new oral anticoagulants has recommended lowering the threshold for initiation of oral anticoagulation for those patients with a stroke risk to 0.9% per year. This aims to create a paradigm shift toward identifying truly low-risk patients, rather than the prior categorization schemes that stratified patients into arbitrary low-, medium-, and high-risk groups. 26 Consequently, accuracy in predicting which patients are at moderate-to-high risk (reflected in c statistics) may be of less importance; all patients who are not low-risk would be recommended to start oral anticoagulation. Increasing the percent on anticoagulants by lowering the threshold of starting anticoagulation is justified by reduced risk of adverse effects with these newer agents, better tolerance with fewer food and medication interactions, and lower risk of major bleeding. However, the validity of this threshold event rate is dependent on underlying assumptions that may be in flux, such as the relationship between dabigatran and myocardial infarction and the reversibility of the novel anticoagulants. Thus, lowering the anticoagulation threshold in guidelines at this point in time may be premature. In our cohort, the newer schema (CHA 2 DS 2 -VASc, NICE, American College of Cardiology/American Heart Association/ESC, and Eighth American College of Chest Physicians) most accurately categorized patients as low risk.
The CHA 2 DS 2 -VASc scheme had the lowest event rate among all low-risk cohorts (0.11 per 100 PY) and is slightly lower than incidence rates in CHA 2 DS 2 -VASc score=0 cohorts in other large registry-based studies. 23, 27 Recent registry data suggest that further risk stratification of patients with CHADS 2 score 0 to 1 with the CHA 2 DS 2 -VASc scheme improves ability to identify truly low-risk patients. 28 The added benefit of finer risk stratification in this CHADS 2 range is highlighted by the event rates of 1.59 per 100 PY with CHADS 2 =0, contrasted against 0.8% (CHA 2 DS 2 -VASc score=0) to 3.23% (CHA 2 DS 2 -VASc score=3). 28 Similar improvement in characterization of low-risk patients by CHA 2 DS 2 -VASc compared with CHADS 2 has also been reported elsewhere. 29 Older 
Limitations
The retrospective, single-center, registry-based observational cohort study design has inherent biases. Certain risk factors may be underdiagnosed or recorded in the medical records, such as vascular disease. However, a more complete vascular history could only reclassify subjects into a higher risk category within the CHA 2 DS 2 -VASc and NICE schemes, potentially decreasing the already low event rates of both schemes' lowand intermediate-risk categories. In addition, there is limited ethnic diversity in the Olmsted County population, being predominantly white although CHADS 2 and CHA 2 DS 2 -VASc have been validated in other nonwhite populations.
Events happening outside of our area or hospital may not have been recorded unless documented on subsequent visits or imaging and may be underreported. Our cohort only required a single episode of AF for inclusion, including single episodes of self-limited, unprovoked symptomatic AF; silent AF is often unrecognized and may be more prevalent than symptomatic paroxysms. 31 Consequently, the classification of AF and number of captured episodes may not be as important when determining risk and deciding whether to anticoagulate. Warfarin was prescribed in Olmsted County on the basis of clinical assessment of risk; thus, reflecting real-world prescribing and compliance seen in similar studies. The above factors have potential to dilute the event rate within our cohort. However, our overall thromboembolic event rate per 100 PY of 2.94 is higher than event rates with other recent studies of real-world populations on anticoagulation. 12, 22, 30 
Conclusions
In this cohort of patients with AF, there was no profound difference in the accuracy of risk prediction with regards to identification of those at high risk of thromboembolism. Identification of the low-risk patient is becoming of greater importance because treatment recommendations shift toward oral anticoagulation (whether with well-controlled adjusted dose warfarin or one of the novel oral anticoagulants) for those in both intermediate-and high-risk groups. The simplicity of the CHA 2 DS 2 -VASc scheme for clinical use and its performance in identifying low-risk patients in several studies make it well suited for this purpose.
